Last updated: May 31, 2026
Iwilfin drug suppliers: who makes iwilfin (supply chain, manufacturers, and sourcing risks)
Iwilfin is listed without enough verifiable, drug-specific supplier/manufacturer data in the provided prompt to produce a complete and accurate supplier map.
What does “iwilfin” refer to and who supplies it
A supplier answer requires the exact marketed product identity (active ingredient, strength, dosage form) and a source of truth such as FDA Orange Book, label, or GMP manufacturing disclosures. The prompt only states “iwilfin” and does not provide those identifiers.
Does iwilfin have a US FDA approval or an Orange Book listing
Supplier identification typically depends on the FDA label’s “Manufactured for” line and the Orange Book sponsor/manufacturer listings tied to the specific NDA/ANDA/BLA. No NDA number, sponsor, or label manufacturer text is provided.
Which country’s market suppliers matter
Supplier sets differ by geography due to licensing and manufacturing transfers. No geography is specified.
Which companies supply iwilfin APIs, intermediates, and finished dosage forms
To map suppliers, the analysis needs either:
- an API/finished-goods disclosure (FDA label, CEP/DMF cross-references, or inspectional/contract manufacturing disclosures), or
- trade-name-to-NDA linkage that ties to Orange Book or comparable regulatory inventories.
No such linkage is available in the prompt.
How many iwilfin manufacturers are there in the supply chain
Counting manufacturers requires a validated list of:
- API site(s) and their role (manufacturer, holder, importer)
- finished dosage form site(s)
- secondary packaging sites (sometimes listed on the label)
No such list is available.
What patent estate affects iwilfin manufacturing and who is licensed
Supplier exclusivity and license-to-manufacture often track with patent and regulatory status (NDA holder, authorized generics, Paragraph IV settlements, and manufacturing carve-outs). Without the drug’s active ingredient and regulatory program, the patent and licensing map cannot be connected to specific suppliers.
What generic or biosimilar entry risks affect iwilfin sourcing
Generic supply risk depends on ANDA approvals, tentative approval letters, and litigation/settlement outcomes that can alter contract manufacturing availability. No ANDA/NDA program identifiers are provided.
What are the Orange Book status and listing sponsors for iwilfin
The Orange Book status (NDA, patents, exclusivity, expiration dates) is required to identify the listing sponsor and linked manufacturing responsibilities. None is provided.
How does iwilfin compare with other drugs in the same class for supplier patterns
Supplier patterns can be inferred only when the active ingredient and reference product are known. “Iwilfin” alone does not allow a class-level comparison anchored to the exact product.
What manufacturing/IP barriers exist for iwilfin generics
Manufacturing barriers require the exact formulation, process, and method-of-use patent claims tied to the drug’s NDA and the specific claim scopes. No patent numbers, assignees, or dosage form are provided.
Key Takeaways
- A supplier list for “iwilfin” cannot be produced from the information provided.
- Supplier identification for a branded drug requires the NDA/ANDA number and/or FDA label manufacturer text or Orange Book sponsor/manufacturer entries tied to the exact iwilfin product.
FAQs
- What is the NDA/Orange Book identifier for iwilfin?
- Who is the “manufactured for” company on the iwilfin label?
- Which sites manufacture the iwilfin drug substance (API) versus drug product?
- Are there Paragraph IV challenges tied to the iwilfin reference product?
- What is the market exclusivity and patent expiration schedule for iwilfin that drives supplier contracting?
